KMPH News and Press, KemPharm Inc From 08/11/22

KemPharm press release ( NASDAQ: KMPH ): Q2 Non-GAAP EPS of -$0.19 misses by $0.05 . Revenue of $1.3M (-89.2% Y/Y) misses by $0.45M . As of June 30, 2022, total cash, cash equivalents and investments were $114.5 million, which was a decrease of $4.6 million com...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.’s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS ® Acquired s...

CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative a...

CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative a...

CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative an...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...

Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION, Fla., June 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (K...

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with...

KemPharm, Inc. (KMPH) Q1 2022 Earnings Conference Call May 12, 2022, 17:00 ET Company Participants Travis Mickle - Co-Founder, President, CEO & Director LaDuane Clifton - CFO, Secretary & Treasurer Conference Call Participants Jason Rando - Tiberend Strategic Advisors Presentation Ope...